ScholarIQanswers from OpenAlex

Response to crizotinib in advanced ALK -rearranged non-small cell lung cancers with different ALK -fusion variants

PaperCitations, authors & open-access status

Response to crizotinib in advanced ALK -rearranged non-small cell lung cancers with different ALK -fusion variants is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Response to crizotinib in advanced ALK -rearranged non-small cell lung cancers with different ALK -fusion variants have?

ScholarIQcitation count

Response to crizotinib in advanced ALK -rearranged non-small cell lung cancers with different ALK -fusion variants has 67 citations in the OpenAlex counts ScholarIQ stores.

When was Response to crizotinib in advanced ALK -rearranged non-small cell lung cancers with different ALK -fusion variants published?

ScholarIQyear

Response to crizotinib in advanced ALK -rearranged non-small cell lung cancers with different ALK -fusion variants has 2018 year in the ScholarIQ index.

What is the open-access status of Response to crizotinib in advanced ALK -rearranged non-small cell lung cancers with different ALK -fusion variants?

ScholarIQoa status

Response to crizotinib in advanced ALK -rearranged non-small cell lung cancers with different ALK -fusion variants has closed oa status in the ScholarIQ index.

What is the DOI of Response to crizotinib in advanced ALK -rearranged non-small cell lung cancers with different ALK -fusion variants?

ScholarIQdoi

The DOI for Response to crizotinib in advanced ALK -rearranged non-small cell lung cancers with different ALK -fusion variants is on the source record.

What is the PMID of Response to crizotinib in advanced ALK -rearranged non-small cell lung cancers with different ALK -fusion variants?

ScholarIQpmid

The PMID for Response to crizotinib in advanced ALK -rearranged non-small cell lung cancers with different ALK -fusion variants is on the source record.

What is the OpenAlex record for Response to crizotinib in advanced ALK -rearranged non-small cell lung cancers with different ALK -fusion variants?

ScholarIQopenalex

The OpenAlex for Response to crizotinib in advanced ALK -rearranged non-small cell lung cancers with different ALK -fusion variants is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial